Trials of Experimental Alzheimer's Drug Disappoint — Physician’s First Watch
Trials of Experimental Alzheimer's Drug Disappoint
Development of the intravenous formulation of an Alzheimer disease drug, bapineuzumab, has been halted after two clinical trials found that patients with mild-to-moderate disease failed to show cognitive or functional improvement, according to a Reuters report.
The drug is a monoclonal antibody that attacks beta-amyloid. In the phase III trial released this week, bapineuzumab did not improve performance in patients without a variation of the gene ApoE4. In July, Pfizer said that the drug also failed in patients with the ApoE4 variation.
Phase II trials of a subcutaneous formulation will continue.